Skip to main content
. 2013 Sep 24;13:435. doi: 10.1186/1471-2407-13-435

Table 5.

Univariate and multivariable Cox regression model for TTP according to dichotomised IC50 drug sensitivity values (above or below the median value) and clinicopathological variables for the CRC subgroup

n = 47 Median TTP
 Log-rank
 Univariate
 Univariate
 Multivariate
Months p HR p p
Treated vs. untreated
 10 vs. 5
 0.06
 0.5
 0.2
 -
Oxaliplatin †
 5 vs. 5
 0.8
 0.9
 0.9
 -
Cisplatin †
 5 vs. 5
 0.8
 0.9
 0.9
 -
Melphalan †
 12 vs. 7
 0.8
 1.1
 0.8
 -
5-FU †
 6 vs. 5
 0.7
 0.9
 0.7
 -
Mitomycin C †
 12 vs. 4
 0.2
 0.6
 0.2
 -
Irinotecan †
 5 vs. 5
 0.9
 1.0
 0.9
 -
Docetaxel †
 10 vs. 4
 0.6
 0.8
 0.6
 -
Doxorubicin †
 12 vs. 1
 0.008
 0.4
 0.009
 0.02
Synch. vs. Metach.
 9 vs. 4
 0.05
 0.5
 0.05
 0.006
Vasc./neural vs. not
 2 vs. 10
 0.05
 2.3
 0.03
 0.12
Mucinous vs. not
 9 vs. 5
 0.12
 0.6
 0.12
 -
Lymph node + vs. not
 6 vs. 7
 0.9
 1.0
 0.9
 -
CC0 vs. CC 1-3 18 vs. 4 0.002 0.3 0.001 0.002

There was missing data concerning TTP in 5 patients.

† Below vs. above the median IC50 value. Low IC50 indicates better sensitivity.

Abbreviations: TTP time to progression, CRC colorectal cancer, Synch synchronous, metach metachronous, vasc/neural vascular or neural invasion, CC completeness of cytoreduction.